. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078

Table 3.

Rosiglitazone meta-analyses for composite outcome

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	P value	No of trials
Peto (fixed)
IPD only	Included	Excluded	None	OR 1.40 (1.16 to 1.69)	0.000	31
IPD+RECORD	Included	Excluded	None	OR 1.20 (1.06 to 1.36)	0.004	32
Mantel-Haenszel (fixed)
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.39 (1.15 to 1.68)	0.001	31
IPD only	Included	Excluded		RR 1.37 (1.14 to 1.64)	0.001	31
IPD+RECORD	Included	Excluded		OR 1.20 (1.06 to 1.36)	0.005	32
IPD+RECORD	Included	Excluded		RR 1.17 (1.05 to 1.31)	0.005	32
IPD only	Included	Included		OR 1.39 (1.15 to 1.68)	0.001	33
IPD only	Included	Included		RR 1.36 (1.14 to 1.63)	0.001	33
IPD+RECORD	Included	Included		OR 1.20 (1.06 to 1.36)	0.005	34
IPD+RECORD	Included	Included		RR 1.17 (1.05 to 1.31)	0.005	34
Dersimonian and Laird (random)
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.33 (1.09 to 1.61)	0.005	31
IPD only	Included	Excluded		RR 1.30 (1.08 to 1.56)	0.005	31
IPD+RECORD	Included	Excluded		OR 1.17 (1.03 to 1.33)	0.02	32
IPD+RECORD	Included	Excluded		RR 1.14 (1.02 to 1.28)	0.02	32
IPD only	Included	Included		OR 1.33 (1.09 to 1.61)	0.005	33
IPD only	Included	Included		RR 1.30 (1.08 to 1.56)	0.005	33
IPD+RECORD	Included	Included		OR 1.17 (1.03 to 1.33)	0.02	34
IPD+RECORD	Included	Included		RR 1.14 (1.02 to 1.28)	0.02	34
Mantel-Haenszel (fixed)
IPD only	Included	Excluded	Treatment arm correction	OR 1.41 (1.16 to 1.70)	0.001	31
IPD only	Included	Excluded		RR 1.38 (1.15 to 1.65)	0.001	31
IPD+RECORD	Included	Excluded		OR 1.20 (1.06 to 1.36)	0.004	32
IPD+RECORD	Included	Excluded		RR 1.18 (1.05 to 1.32)	0.004	32
IPD only	Included	Included		OR 1.40 (1.16 to 1.70)	0.001	33
IPD only	Included	Included		RR 1.38 (1.15 to 1.65)	0.001	33
IPD+RECORD	Included	Included		OR 1.20 (1.06 to 1.36)	0.004	34
IPD+RECORD	Included	Included		RR 1.18 (1.05 to 1.32)	0.004	34
Dersimonian and Laird (random)
IPD only	Included	Excluded	Treatment arm correction	OR 1.33 (1.09 to 1.61)	0.005	31
IPD only	Included	Excluded		RR 1.30 (1.08 to 1.56)	0.005	31
IPD+RECORD	Included	Excluded		OR 1.17 (1.03 to 1.33)	0.02	32
IPD+RECORD	Included	Excluded		RR 1.14 (1.02 to 1.28)	0.20	32
IPD only	Included	Included		OR 1.33 (1.09 to 1.61)	0.005	33
IPD only	Included	Included		RR 1.30 (1.08 to 1.56)	0.005	33
IPD+RECORD	Included	Included		OR 1.17 (1.03 to 1.33)	0.02	34
IPD+RECORD	Included	Included		RR 1.14 (1.02 to 1.28)	0.02	34

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of composite events observed among the total population of patients were as follows: IPD only, rosiglitazone population: 274 events among 11 837 patients; IPD only, control population: 219 events among 9319 patients; RECORD, rosiglitazone population: 333 events among 2226 patients; RECORD, control population: 316 events among 2232 patients.